Copyright
©The Author(s) 2022.
World J Gastroenterol. Jan 21, 2022; 28(3): 275-289
Published online Jan 21, 2022. doi: 10.3748/wjg.v28.i3.275
Published online Jan 21, 2022. doi: 10.3748/wjg.v28.i3.275
Intervention/ Treatment | Mode of action | Dose | Route | ClinicalTrials.gov Identifier |
Ronapreve/REGN-COV2 (REGN10933 and REGN10987) | Monoclonal antibodies against spike proteins | 8 g once, or 4 g twice | IV | NCT04425629 |
Lopinavir/Ritonavir | Inhibitor of the HIV protease and cytochrome P-450 CYP3A | 200/ 50 mg; (4 tablets twice a day on day 1 followed by 2 tablets twice a day for 9 d) | Oral | NCT04403100 |
Remdesivir (RDV, GS-5734, Veklury) | Inhibitor of RNA-dependent RNA polymerase | 200 mg on day 1 followed by 100 mg for 4-9 d | IV | NCT04292899 |
Hyperimmune Plasma (COV19-PLASMA) | Immunotherapy | 250-300 mL up to 3 times over 5 d | IV | NCT04321421 |
Tocilizumab (TCZ, ROACTEMRA) | Humanized anti-IL6 receptor monoclonal antibody | 8 mg/kg single infusion, up to 800 mg | IV | NCT04320615 |
Sarilumab (Kevzara, REGN88, SAR153191) | Monoclonal antibody against IL-6 receptor alpha | 200 mg or 400 mg; single dose and multiple doses | IV | NCT04315298 |
Anakinra (KINERET) | Monoclonal antibody against the IL-1 receptor | 100 mg daily up to 28 d | SC | NCT04330638 |
Siltuximab (SYLVANT) | Chimeric anti-IL-6 antibody | 11 mg/kg single infusion | IV | NCT04330638 |
Eculizumab | Monoclonal antibody against complement protein C5 | 900 mg every 7 d | IV | NCT04288713 |
Methyl-prednisolone (MP) | Immunosuppression against cytokine storm | 80 mg/kg IV bolus, followed by infusion of 80 mg/d for at least 8 d and then oral MP 16 mg or 20 mg IV twice daily | Oral-IV | NCT04323592 |
Heparin | Antithrombotic agents | 10 units/kg/h | IV | NCT04367831 |
Enoxaparin (Lovenox) | Antithrombotic agents | 1 mg/kg | SC | NCT04367831 |
Dexamethasone | Immunosuppression against cytokine storm | 20 mg/d (5 d) then 10 mg/d (5 d) | IV | NCT04325061 |
Vitamin C | Antioxidant | 12 g infusion twice a day for 7 d | IV | NCT04264533 |
Melatonin | Antioxidant | 3 or 30 mg three times a day for 14 d | Oral | NCT04784754 |
CoQ10 | Antioxidant | 500 mg/day for 6 wk | Oral | NCT04960215 |
- Citation: Tarnawski AS, Ahluwalia A. Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. World J Gastroenterol 2022; 28(3): 275-289
- URL: https://www.wjgnet.com/1007-9327/full/v28/i3/275.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i3.275